home / stock / aim / aim news


AIM News and Press, AIM ImmunoTech Inc. From 12/21/20

Stock Information

Company Name: AIM ImmunoTech Inc.
Stock Symbol: AIM
Market: NYSE
Website: aimimmuno.com

Menu

AIM AIM Quote AIM Short AIM News AIM Articles AIM Message Board
Get AIM Alerts

News, Short Squeeze, Breakout and More Instantly...

AIM - AJRD, AJIO, NK and LAZR among premarket gainers

EyeGate Pharmaceuticals (EYEG) +87% as it acquires Panoptes Pharma.NantKwest (NK) +32% as its partner, ImmunityBio, achieves primary endpoint in bladder cancer study.RealPage (RP) +31% as Thoma Bravo has agreed to buy the company for $9.6B.China Customer Relations Centers (CCRC...

AIM - AIM ImmunoTech' Ampligen an Orphan Drug in U.S. for the treatment of pancreatic cancer

The FDA grants Orphan Drug designation to AIM ImmunoTech' (AIM) drug Ampligen (rintatolimod) for the treatment of pancreatic cancer.The Orphan Drug tag may provide incentivize the treatment of therapies to treat unmet medical needs by providing a company with seven years o...

AIM - AIM ImmunoTech Inc.'s Drug Ampligen Awarded FDA's Orphan Drug Designation Status for the Treatment of Pancreatic Cancer

OCALA, Fla., Dec. 21, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the U.S. Food and Drug Admi...

AIM - 5 Best Penny Stocks To Buy Now According To Insiders

Insiders Consider These Penny Stocks To Buy Now At some point, you’ve been introduced to penny stocks . Whether it was by a “buddy” with a “hot tip” or you saw something on a movie, you’ve been excited by something relating to these cheap st...

AIM - Healthcare tops premarket gainers list

CNS Pharmaceuticals (CNSP) +62%.Cyclo Therapeutics (CYTH) +47%.Mereo BioPharma Group (MREO) +38% on licensing pact with Ultragenyx.DermTech (DMTK) +23% after announcing topline results from its TRUST Study of the company’s non-invasive melanoma rule-out test, the Pigmented Le...

AIM - Dosing underway in AIM ImmunoTech's Ampligen in combo trial in COVID-19 patients with cancer

The first patient have been dosed and treated in AIM ImmunoTech (AIM) Roswell Park Comprehensive Cancer Center's Phase 1/2a clinical study of the effectiveness of rintatolimod (Ampligen) in combination with interferon alpha-2b in treating cancer patients with mild or moderate COVID-19.Fu...

AIM - AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19

OCALA, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced developments in its work to develop new treatments or preventive strategies for COVID-19, the disease caused by SARS-CoV-2. First, AIM reports that Roswell Park Comprehensive Cancer...

AIM - AHT, FCEL, AIM and MARA among midday movers

Gainers: DPW Holdings (DPW) +179%.Ideanomics (IDEX) +65%.Fuel Tech (FTEK) +61%.Greenland Technologies (GTEC) +52%.Kaixin Auto (KXIN) +52%.FuelCell Energy (FCEL) +45%.CIIG Merger (CIIC) +37%.Graybug Vision (GRAY) +36%.Beam Global (BEEM) +35%.Marathon Patent (MARA) +33%.Losers: B...

AIM - Medigus, 180 Life Sciences leads healthcare gainers; Bellerophon Therapeutics, BioLineRx among major losers

Gainers: Medigus (MDGS) +36%, 180 Life Sciences (ATNF) +35%, Graybug Vision (GRAY) +23%, Trinity Biotech (TRIB) +18%, Accuray (ARAY) +14%.Losers: Bellerophon Therapeutics (BLPH) -18%, BioLineRx (BLRX) -13%, AIM ImmunoTech (AIM) -11%, iBio...

AIM - Root, Niu Technologies leads the premarket losers pack

Ashford Hospitality Trust (AHT) -21% on update of exchange offers for all outstanding series of preferred stock.BioLineRx (BLRX) -13% on Q3 earnings release.AIM ImmunoTech (AIM) -8% after AIM and Shionogi terminated their material transfer agreement.Niu Technologies (...

Previous 10 Next 10